Compare KREF & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KREF | OMER |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.9M | 628.9M |
| IPO Year | 2017 | 2009 |
| Metric | KREF | OMER |
|---|---|---|
| Price | $8.44 | $10.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $10.71 | ★ $27.50 |
| AVG Volume (30 Days) | 843.1K | ★ 1.7M |
| Earning Date | 10-21-2025 | 11-13-2025 |
| Dividend Yield | ★ 11.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,012,000.00 | N/A |
| Revenue This Year | $16.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.78 | $2.95 |
| 52 Week High | $11.74 | $13.60 |
| Indicator | KREF | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 71.19 |
| Support Level | $8.38 | $9.31 |
| Resistance Level | $8.63 | $11.03 |
| Average True Range (ATR) | 0.17 | 0.73 |
| MACD | 0.04 | 0.18 |
| Stochastic Oscillator | 70.34 | 97.89 |
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.